Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Abstract Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of cancers. PD-L1 is constitutively expressed in certain tumors and host immune cells, and its expression can be induced or maintained by many factors. The expression of P...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Cell & Bioscience |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13578-018-0232-4 |
id |
doaj-900e408d7460421daf92c36591ca2348 |
---|---|
record_format |
Article |
spelling |
doaj-900e408d7460421daf92c36591ca23482020-11-24T21:06:14ZengBMCCell & Bioscience2045-37012018-05-01811810.1186/s13578-018-0232-4Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?Fei Tang0Pan Zheng1Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of MedicineDivision of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of MedicineAbstract Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of cancers. PD-L1 is constitutively expressed in certain tumors and host immune cells, and its expression can be induced or maintained by many factors. The expression of PD-L1 on tumor tissues has been reported to be positively correlated with the efficacy of anti-PD-1/PD-L1 therapy in patients. However, multiple clinical trials indicate that patients with PD-L1-negative tumors also respond to this blockade therapy, which suggests the potential contribution of PD-L1 from host immune cells. Recently, six articles independently evaluated and verified the contributions of PD-L1 from tumor versus non-tumor cells in various mouse tumor models. These studies confirmed that PD-L1 on either tumor cells or host immune cells contributes to tumor escape, and the relative contributions of PD-L1 on these cells seem to be context-dependent. While both tumor- and host-derived PD-L1 can play critical roles in immune suppression, differences in tumor immunogenicity appear to underlie their relative importance. Notably, these reports highlight the essential roles of PD-L1 from host myeloid cells in negatively regulating T cell activation and limiting T cell trafficking. Therefore, comprehensive evaluating the global PD-L1 expression, rather than monitoring PD-L1 expression on tumor cells alone, should be a more accurate way for predicting responses in PD-1/PD-L1 blockade therapy in cancer patients.http://link.springer.com/article/10.1186/s13578-018-0232-4PD-L1PD-1/PD-L1 blockadeCancer immunotherapyHost immune cellsImmune evasionImmune therapeutic effect |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fei Tang Pan Zheng |
spellingShingle |
Fei Tang Pan Zheng Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy? Cell & Bioscience PD-L1 PD-1/PD-L1 blockade Cancer immunotherapy Host immune cells Immune evasion Immune therapeutic effect |
author_facet |
Fei Tang Pan Zheng |
author_sort |
Fei Tang |
title |
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy? |
title_short |
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy? |
title_full |
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy? |
title_fullStr |
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy? |
title_full_unstemmed |
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy? |
title_sort |
tumor cells versus host immune cells: whose pd-l1 contributes to pd-1/pd-l1 blockade mediated cancer immunotherapy? |
publisher |
BMC |
series |
Cell & Bioscience |
issn |
2045-3701 |
publishDate |
2018-05-01 |
description |
Abstract Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of cancers. PD-L1 is constitutively expressed in certain tumors and host immune cells, and its expression can be induced or maintained by many factors. The expression of PD-L1 on tumor tissues has been reported to be positively correlated with the efficacy of anti-PD-1/PD-L1 therapy in patients. However, multiple clinical trials indicate that patients with PD-L1-negative tumors also respond to this blockade therapy, which suggests the potential contribution of PD-L1 from host immune cells. Recently, six articles independently evaluated and verified the contributions of PD-L1 from tumor versus non-tumor cells in various mouse tumor models. These studies confirmed that PD-L1 on either tumor cells or host immune cells contributes to tumor escape, and the relative contributions of PD-L1 on these cells seem to be context-dependent. While both tumor- and host-derived PD-L1 can play critical roles in immune suppression, differences in tumor immunogenicity appear to underlie their relative importance. Notably, these reports highlight the essential roles of PD-L1 from host myeloid cells in negatively regulating T cell activation and limiting T cell trafficking. Therefore, comprehensive evaluating the global PD-L1 expression, rather than monitoring PD-L1 expression on tumor cells alone, should be a more accurate way for predicting responses in PD-1/PD-L1 blockade therapy in cancer patients. |
topic |
PD-L1 PD-1/PD-L1 blockade Cancer immunotherapy Host immune cells Immune evasion Immune therapeutic effect |
url |
http://link.springer.com/article/10.1186/s13578-018-0232-4 |
work_keys_str_mv |
AT feitang tumorcellsversushostimmunecellswhosepdl1contributestopd1pdl1blockademediatedcancerimmunotherapy AT panzheng tumorcellsversushostimmunecellswhosepdl1contributestopd1pdl1blockademediatedcancerimmunotherapy |
_version_ |
1716766225200054272 |